ARGENICA TO BE GRANTED PATENT PROTECTION IN THE UNITED STATES, ONE OF THE WORLD'S LARGEST HEALTHCARE MARKETS

Highlights:

- *The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for claims incorporating the use of Argenica's lead drug candidate ARG-007 as a therapeutic in lead applications of stroke, TBI and HIE.*

- *This Notice of Allowance confirms that the Neuroprotective Peptide patent application is allowed for issuance as a patent and the Company anticipates formal granting of the patent to occur within months.*

- *Achieving patent protection in the US is a major milestone for Argenica, as it enables potential future commercialisation of ARG-007 in one of the biggest healthcare markets in the world.*

- *The patent claims also cover the use of ARG-007 as a treatment for Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease, motor neuron disease, neuropathic pain, spinal cord injury, and epilepsy.*

- *Argenica also has granted patents in the large markets of Europe, Japan and China, and will continue to implement patent life extension and new intellectual property strategies.*

Perth, Australia; 9 December 2021 - Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application number 16/041,483 relating to the use of ARG-007. The patent covers the use of ARG-007 as a therapeutic compound to prevent brain cell death in Argenica's lead applications of stroke, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).

This Notice of Allowance confirms that the patent application "Neuroprotective Peptides" is allowed for issuance as a patent, and the Company anticipates formal granting of the patent to occur within months.

Commenting on the issue of the Notice of Allowance, Argenica CEO, Dr Liz Dallimore said: "We are delighted with the USPTO's issue of the Notice of Allowance for patenting ARG-007 as a novel

treatment for stroke, TBI, HIE, and other neurological conditions. These are conditions with huge unmet medical needs in the US and represent large addressable markets that the company will look to target. The granting of this patent will strengthen our ability to enter into commercial negotiations with US pharmaceutical companies in the future."

ARG-007 is a neuroprotective therapeutic drug which has shown efficacy in animal models to reduce brain cell death following stroke, TBI and HIE. The allowance of the claims in Argenica's US patent are essential to potentially commercialising ARG-007 in our lead applications of stroke, TBI and HIE in the US. Each year in the US, approximately 795,000 people suffer a stroke[1], 1.5 million people sustain a TBI[2], and approximately 4 in every 1000 live term births and up to 60% of pre-term infants suffer HIE[3].

Importantly, the patent claims also cover the use of ARG-007 in Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease, motor neuron disease, neuropathic pain, spinal cord injury, and epilepsy. Should the Company generate the efficacy data required to progress the development of ARG-007 for these additional devastating neurological conditions at a future point in time, the patent provides confidence that ARG-007 can be commercialised in these broader applications in the US.

Argenica already has granted patents in the largest addressable markets of the EU (validated in 11 key countries), Japan and China. A summary of patent coverage is provided below:

Jurisdiction	Progress	Number	Protection coverage
Europe	Granted	EU3063168	Exp: 30/10/2034
Japan	Granted	Japan 6495270	Exp: 30/10/2034
China	Granted	ZL2014800719713	Exp: 30/10/2034
US	Granted (Q1 CY22) *	US16/041,483	TBC

**Timing subject to change*

Notably, these patents are 100% owned by Argenica and the Company's IP assignment is free of royalties or other encumbrances.

This announcement has been approved for release by the Board of Argenica

For more information please contact: info@argenica.com.au

[1] https://www.cdc.gov/stroke/facts.htm
[2] https://www.cdc.gov/traumaticbraininjury/pubs/tbi_report_to_congress.html
[3] https://ufhealth.org/hypoxic-ischemic-encephalopathy-hie

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicity before commencing Phase 1 clinical trials in humans. The aim is for our therapeutic to be administered by first responders to protect brain tissue against damage during a stroke with further potential to enhance recovery once a stroke has taken place.